Regulatory Focus

Woodcock: Post-COVID, new flexibility could boost cancer trial diversity

09 April 2021 | By Kari Oakes

Everything from digitizing the informed consent process to enabling remote, “no-touch” visits to telemedicine and better use of the ...

Regulatory Exchange